【摘要】 目的:探讨消化道肿瘤患者化疗相关性腹泻的治疗方法。方法:62例化疗相关性腹泻患者随机分成3组,A组口服洛哌丁胺,B组皮下注射奥曲肽,C组皮下注射奥曲肽的同时口服培菲康。观察患者治疗前后的KPS评分和腹泻的治疗效果并进行统计学分析。结果:A组患者治疗前后KPS评分无显著性差异,B组和C组治疗后KPS评分明显高于治疗前。治疗后B组KPS评分高于A组低于C组。B组的腹泻治疗效果与A组和C组都有明显差异。结论:奥曲肽对化疗相关性腹泻有较好治疗效果,奥曲肽和培菲康共同应用的治疗效果更加明显。更多还原

【Abstract】 Objective:To explore the therapeutic regimen for chemotherapy-induced diarrhea (CID) in patients with digestive tract carcinoma. Methods: Sixty-two patients with CID were divided into three groups randomly. Group A took loperamide orally. Group B was subcutaneously injected octreotide. Group C was subcutaneously injected octreotide and administered Birid Triple Viable (BIFICO) simultaneously. The Karnofsky performance status (KPS) score was recorded and the therapeutic outcome was observed. Results: There was no significant difference in KPS score for group A before and after therapy. The KPS score was significantly higher in Group B and Group C after therapy. The KPS score for Group B was higher than that in Group A and lower than that in Group C. The therapeutic outcome of Group B was significantly different with Group A and group C. Conclusion: Octreotide has better efficacy in the treatment of CID. Combination therapy with octreotide and BIFICO mag achieve more apparent outcome.更多还原